Indian pharmaceutical company Zydus Lifesciences reported a 53.3% increase in quarterly profit, driven by strong sales in the domestic and US markets. The company’s net profit for the second quarter of FY 2024 was INR 801 crore ($96.2 million), compared to INR 523 crore in the same period last year. Zydus’ total revenue rose 9.1% to INR 4,369 crore, with the US formulation segment accounting for 44% of the business. The company expects sustained profitability and aims for EBITDA margins of over 24% in the current fiscal year.
Business News: Latest News on Business, Stock Markets, Financial News, India Business & World Business News